Analytical Data
-
Gene name
SLC25A30
- Application
-
Alternative Names
Solute carrier family 25 member 30
-
Species
Human
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q5SVS4
-
Expression Region
1-291aa
-
Molecular Weight
48.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The SLC25A30 gene encodes a mitochondrial carrier protein that plays a crucial role in the transport of metabolites across the inner mitochondrial membrane. Recent studies have highlighted its involvement in mitochondrial function, cellular metabolism, and energy production. Dysregulation or mutations in SLC25A30 have been linked to various metabolic disorders and mitochondrial diseases, underscoring the importance of understanding its functional mechanisms. Research into the recombinant expression of SLC25A30 is vital for elucidating its structural characteristics and transport mechanisms, which are essential for elucidating its biological roles. By producing recombinant SLC25A30 protein in a controlled laboratory setting, scientists aim to investigate its substrate specificity, interaction with other mitochondrial proteins, and participation in metabolic pathways. This research can potentially lead to novel therapeutic strategies for conditions associated with mitochondrial dysfunction and provide insights into the broader field of mitochondrial biology. Furthermore, the ability to study SLC25A30 in vitro allows for the development of assays that can be used in drug screening and the exploration of its role as a potential drug target. Overall, the study of recombinant SLC25A30 protein is a promising avenue for advancing our understanding of mitochondrial dynamics and their implications for human health and disease.
